Clinical Trial Update: Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating durvalumab plus chemotherapy in untreated extensive-stage small cell lung cancer has completed and posted results in January 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Small Cell Lung Carcinoma Extensive Disease | Phase 3 | Status: COMPLETED | Results posted: 2025-01-07